期刊： EXPERT OPINION ON THERAPEUTIC PATENTS, 2023; 33 (1)
IntroductionThe nuclear factor erythroid 2-related factor 2 (Nrf2) is a pivotal transcription factor that controls the expression of numerous cytoprot......
期刊： EXPERT OPINION ON THERAPEUTIC PATENTS, 2023; ()
Introduction: beta-Lactams, which include monobactams, remain the most important class of antibiotics worldwide. Aztreonam, the only monobactam in cli......
期刊： EXPERT OPINION ON THERAPEUTIC PATENTS, 2023; 33 (10)
IntroductionMatrix metalloproteinases (MMPs) are strongly interlinked with the progression and mechanisms of several life-threatening diseases includi......
期刊： EXPERT OPINION ON THERAPEUTIC PATENTS, 2023; 33 (3)
Introduction: Leishmaniasis is an important disease caused by parasites of the Leishmania. Due to the urgent need for financial incentives and researc......
期刊： EXPERT OPINION ON THERAPEUTIC PATENTS, 2023; 33 (12)
Introduction: Thymosins are small proteins found mainly in the thymus. They are involved in several biological processes, including immunoregulation, ......
期刊： EXPERT OPINION ON THERAPEUTIC PATENTS, 2023; ()
Introduction: Thymosins are small proteins found mainly in the thymus. They are involved in several biological processes, including immunoregulation, ......
期刊： EXPERT OPINION ON THERAPEUTIC PATENTS, 2023; 33 (4)
IntroductionThe dysregulation of CDK9 protein is greatly related to the proliferation and differentiation of various cancers due to its key role in th......
期刊： EXPERT OPINION ON THERAPEUTIC PATENTS, 2023; 33 (4)
IntroductionEZH2 is an important epigenetic regulator that forms the PRC2 complex with SUZ12, EED and RbAp46/48. As the key catalytic subunit of PRC2,......
期刊： EXPERT OPINION ON THERAPEUTIC PATENTS, 2023; 33 (5)
IntroductionEmerging immunotherapies are pushing the boundaries of cancer treatment, with chimeric antigen receptor (CAR)-T cell therapy being one of ......
期刊： EXPERT OPINION ON THERAPEUTIC PATENTS, 2023; ()
Introduction: Abnormal expression of epidermal growth factor receptor (EGFR) contributes to tumor development, especially in non-small cell lung cance......
期刊： EXPERT OPINION ON THERAPEUTIC PATENTS, 2023; 33 (3)
IntroductionChagas disease is a neglected, endemic disease in 21 countries, spreading to non-endemic countries too. Like other neglected diseases affe......
期刊： EXPERT OPINION ON THERAPEUTIC PATENTS, 2023; 33 (4)
IntroductionAnaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, has emerged as a promising drug target f......
期刊： EXPERT OPINION ON THERAPEUTIC PATENTS, 2023; 33 (6)
IntroductionMARCKS protein, a protein kinase C (PKC) substrate, is known to be at the intersection of several intracellular signaling pathways and pla......
期刊： EXPERT OPINION ON THERAPEUTIC PATENTS, 2023; 33 (6)
IntroductionThe mitogen-activated protein kinase (MAPK) family consist of p38 MAP kinases, c-Jun N-terminal kinases (JNKs) and extracellular signal-re......
